Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lilly's Growth Will Come From Alliances, Not Merger, VP Lechleiter Says

Executive Summary

Partnership deals - as opposed to a merger - offer Lilly its best opportunities for growth, Lilly Senior VP-Pharmaceutical Products John Lechleiter said.

You may also be interested in...

DuPont/Barr Enter Into Legal Truce With Five Product Promotion Accord

DuPont expects to begin marketing a Barr-developed oncology product in the first quarter of 2001 under an agreement reached by the two companies in their Coumadin dispute.

Glaxo SmithKline U.S. Marketing Could Reach 250,000 MDs In One Week

The combined Glaxo SmithKline U.S. sales force would be able to call on 250,000 physicians during the first week of a major product launch, the companies told a Jan. 17 London press briefing on their proposed merger.

Merck Maintains Merger-Free Philosophy; Co-Promotions Also Ruled Out

Merck will refrain from entering into co-promotion agreements to take advantage of its sales force capacity, CEO Raymond Gilmartin told securities analysts Dec. 9 at the company's Whitehouse Station, N.J. headquarters.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts